Closely-held Clene Nanomedicine is developing catalytic drugs to treat neurodegenerative diseases, using its clean surface nanocrystal (CSN) therapeutics platform to increase cellular bioenergy. “We’re the first...
By Len Zehr Flex Pharma (NASDAQ:FLKS) expects to report clinical readouts in 2018 from three Phase 2 studies of its anti-cramping drug candidate, FLX-787, in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth...
By Len Zehr Kadimastem (TASE:KDST) hopes its pre-IND meeting with the FDA in November will outline a protocol for a Phase 1/2a clinical trial of its stem cell therapy for the treatment for Amyotrophic Lateral Sclerosis...